View in EDS HTML Full Text PDF Full Text

Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review.

Saved in:
Bibliographic Details
Title: Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review.
Authors: Rice, Lauren J., Cannon, Lisa, Dadlani, Navin, Cheung, Melissa Mei Yin, Einfeld, Stewart L., Efron, Daryl, Dossetor, David R., Elliott, Elizabeth J.
Source: European Child & Adolescent Psychiatry. Feb2024, Vol. 33 Issue 2, p505-526. 22p.
Subjects: Drug efficacy, Psychology information storage & retrieval systems, Medical databases, Medical information storage & retrieval systems, Systematic reviews, Tourette syndrome, Neurologic manifestations of general diseases, Child psychopathology, Fragile X syndrome, Descriptive statistics, Cannabinoids, MEDLINE, Fetal alcohol syndrome, Evaluation, Children, Adolescence
Abstract: A better understanding of the endocannabinoid system and a relaxation in regulatory control of cannabis globally has increased interest in the medicinal use of cannabinoid-based products (CBP). We provide a systematic review of the rationale and current clinical trial evidence for CBP in the treatment of neuropsychiatric and neurodevelopmental disorders in children and adolescents. A systematic search of MEDLINE, Embase, PsycINFO, and the Cochrane Central Register of Trials was performed to identify articles published after 1980 about CBP for medical purposes in individuals aged 18 years or younger with selected neuropsychiatric or neurodevelopmental conditions. Risk of bias and quality of evidence was assessed for each article. Of 4466 articles screened, 18 were eligible for inclusion, addressing eight conditions (anxiety disorders (n = 1); autism spectrum disorder (n = 5); foetal alcohol spectrum disorder (n = 1); fragile X syndrome (n = 2); intellectual disability (n = 1); mood disorders (n = 2); post-traumatic stress disorder (n = 3); and Tourette syndrome (n = 3)). Only one randomised controlled trial (RCT) was identified. The remaining seventeen articles included one open-label trial, three uncontrolled before-and-after trials, two case series and 11 case reports, thus the risk of bias was high. Despite growing community and scientific interest, our systematic review identified limited and generally poor-quality evidence for the efficacy of CBP in neuropsychiatric and neurodevelopmental disorders in children and adolescents. Large rigorous RCTs are required to inform clinical care. In the meantime, clinicians must balance patient expectations with the limited evidence available. [ABSTRACT FROM AUTHOR]
Copyright of European Child & Adolescent Psychiatry is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 175455052
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Rice%2C+Lauren+J%2E%22">Rice, Lauren J.</searchLink><br /><searchLink fieldCode="AR" term="%22Cannon%2C+Lisa%22">Cannon, Lisa</searchLink><br /><searchLink fieldCode="AR" term="%22Dadlani%2C+Navin%22">Dadlani, Navin</searchLink><br /><searchLink fieldCode="AR" term="%22Cheung%2C+Melissa+Mei+Yin%22">Cheung, Melissa Mei Yin</searchLink><br /><searchLink fieldCode="AR" term="%22Einfeld%2C+Stewart+L%2E%22">Einfeld, Stewart L.</searchLink><br /><searchLink fieldCode="AR" term="%22Efron%2C+Daryl%22">Efron, Daryl</searchLink><br /><searchLink fieldCode="AR" term="%22Dossetor%2C+David+R%2E%22">Dossetor, David R.</searchLink><br /><searchLink fieldCode="AR" term="%22Elliott%2C+Elizabeth+J%2E%22">Elliott, Elizabeth J.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22European+Child+%26+Adolescent+Psychiatry%22">European Child & Adolescent Psychiatry</searchLink>. Feb2024, Vol. 33 Issue 2, p505-526. 22p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Drug+efficacy%22">Drug efficacy</searchLink><br /><searchLink fieldCode="DE" term="%22Psychology+information+storage+%26+retrieval+systems%22">Psychology information storage & retrieval systems</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+databases%22">Medical databases</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+information+storage+%26+retrieval+systems%22">Medical information storage & retrieval systems</searchLink><br /><searchLink fieldCode="DE" term="%22Systematic+reviews%22">Systematic reviews</searchLink><br /><searchLink fieldCode="DE" term="%22Tourette+syndrome%22">Tourette syndrome</searchLink><br /><searchLink fieldCode="DE" term="%22Neurologic+manifestations+of+general+diseases%22">Neurologic manifestations of general diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Child+psychopathology%22">Child psychopathology</searchLink><br /><searchLink fieldCode="DE" term="%22Fragile+X+syndrome%22">Fragile X syndrome</searchLink><br /><searchLink fieldCode="DE" term="%22Descriptive+statistics%22">Descriptive statistics</searchLink><br /><searchLink fieldCode="DE" term="%22Cannabinoids%22">Cannabinoids</searchLink><br /><searchLink fieldCode="DE" term="%22MEDLINE%22">MEDLINE</searchLink><br /><searchLink fieldCode="DE" term="%22Fetal+alcohol+syndrome%22">Fetal alcohol syndrome</searchLink><br /><searchLink fieldCode="DE" term="%22Evaluation%22">Evaluation</searchLink><br /><searchLink fieldCode="DE" term="%22Children%22">Children</searchLink><br /><searchLink fieldCode="DE" term="%22Adolescence%22">Adolescence</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: A better understanding of the endocannabinoid system and a relaxation in regulatory control of cannabis globally has increased interest in the medicinal use of cannabinoid-based products (CBP). We provide a systematic review of the rationale and current clinical trial evidence for CBP in the treatment of neuropsychiatric and neurodevelopmental disorders in children and adolescents. A systematic search of MEDLINE, Embase, PsycINFO, and the Cochrane Central Register of Trials was performed to identify articles published after 1980 about CBP for medical purposes in individuals aged 18 years or younger with selected neuropsychiatric or neurodevelopmental conditions. Risk of bias and quality of evidence was assessed for each article. Of 4466 articles screened, 18 were eligible for inclusion, addressing eight conditions (anxiety disorders (n = 1); autism spectrum disorder (n = 5); foetal alcohol spectrum disorder (n = 1); fragile X syndrome (n = 2); intellectual disability (n = 1); mood disorders (n = 2); post-traumatic stress disorder (n = 3); and Tourette syndrome (n = 3)). Only one randomised controlled trial (RCT) was identified. The remaining seventeen articles included one open-label trial, three uncontrolled before-and-after trials, two case series and 11 case reports, thus the risk of bias was high. Despite growing community and scientific interest, our systematic review identified limited and generally poor-quality evidence for the efficacy of CBP in neuropsychiatric and neurodevelopmental disorders in children and adolescents. Large rigorous RCTs are required to inform clinical care. In the meantime, clinicians must balance patient expectations with the limited evidence available. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of European Child & Adolescent Psychiatry is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=175455052
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00787-023-02169-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 22
        StartPage: 505
    Subjects:
      – SubjectFull: Drug efficacy
        Type: general
      – SubjectFull: Psychology information storage & retrieval systems
        Type: general
      – SubjectFull: Medical databases
        Type: general
      – SubjectFull: Medical information storage & retrieval systems
        Type: general
      – SubjectFull: Systematic reviews
        Type: general
      – SubjectFull: Tourette syndrome
        Type: general
      – SubjectFull: Neurologic manifestations of general diseases
        Type: general
      – SubjectFull: Child psychopathology
        Type: general
      – SubjectFull: Fragile X syndrome
        Type: general
      – SubjectFull: Descriptive statistics
        Type: general
      – SubjectFull: Cannabinoids
        Type: general
      – SubjectFull: MEDLINE
        Type: general
      – SubjectFull: Fetal alcohol syndrome
        Type: general
      – SubjectFull: Evaluation
        Type: general
      – SubjectFull: Children
        Type: general
      – SubjectFull: Adolescence
        Type: general
    Titles:
      – TitleFull: Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rice, Lauren J.
      – PersonEntity:
          Name:
            NameFull: Cannon, Lisa
      – PersonEntity:
          Name:
            NameFull: Dadlani, Navin
      – PersonEntity:
          Name:
            NameFull: Cheung, Melissa Mei Yin
      – PersonEntity:
          Name:
            NameFull: Einfeld, Stewart L.
      – PersonEntity:
          Name:
            NameFull: Efron, Daryl
      – PersonEntity:
          Name:
            NameFull: Dossetor, David R.
      – PersonEntity:
          Name:
            NameFull: Elliott, Elizabeth J.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: Feb2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 10188827
          Numbering:
            – Type: volume
              Value: 33
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: European Child & Adolescent Psychiatry
              Type: main
ResultId 1